BridgeBio Pharma (BBIO) Stock
Fundamentals
Compare with BBIO
Recent news

BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status
BBIO

BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?
BBIO

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
BBIO

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
BBIO
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 38.48
- MACD 12/26/9
- -2.60
- EMA 9 of MACD
- -2.97
- MACD histogram
- 0.37
- SMA 50
- $75.62
- Price below SMA 50
- EMA 50
- $72.56
- Price below EMA 50
- SMA 200
- $73.50
- Price below SMA 200
- EMA 200
- $72.34
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 6, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 11 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.54 for this quarter. The company has not yet shared when it is announcing earnings.
Latest news

BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status
BBIO

BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?
BBIO

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
BBIO

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
BBIO

$19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers
$19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers
BBIO

BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum
BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum
BBIO

Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue
Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue
BBIO

Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?
Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?
BBIO

BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.
BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.
BBIO

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
BBIO
News tone: automated (AI) classification of the article's content, not a price prediction.
About BridgeBio Pharma
BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio’s pipeline of over 30 development programs includes product candidates ranging from early discovery to late-stage development.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Neil Kumar Ph.D. | Co-Founder, CEO & Director | 1979 |
| Dr. Thomas Trimarchi Ph.D. | CFO & President | 1985 |
| Dr. Charles J. Homcy M.D. | Co-Founder, Chairman of Pharmaceuticals & Lead Director | 1948 |
| Dr. Frank P. McCormick Ph.D. | Co-Founder, Chairman of Oncology & Director | 1950 |
| Ms. Maricel M. Apuli | Chief Accounting Officer | 1977 |
| Dr. Uma Sinha Ph.D. | Chief Scientific Officer | 1958 |
| Dr. Richard H. Scheller Ph.D. | Chairman of Research & Development | 1953 |
| Mr. Eli M. Wallace Ph.D. | Chief Scientific Officer of Oncology | 1967 |
| Dr. Eric Michael David J.D., M.D., Ph.D. | Chief Executive Officer of Gene Therapy | 1972 |
| Mr. Matthew Outten CPC, MBA | Chief Commercial Officer | 1974 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Technical indicators
- RSI 14
- 38.48
- MACD 12/26/9
- -2.60
- EMA 9 of MACD
- -2.97
- MACD histogram
- 0.37
- SMA 50
- $75.62
- Price below SMA 50
- EMA 50
- $72.56
- Price below EMA 50
- SMA 200
- $73.50
- Price below SMA 200
- EMA 200
- $72.34
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 6, 2026. Technical data, not a recommendation.
Analyst views
11 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $93.00
- Average
- $106.82
- High
- $120.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +11.9 | -21.9 | -57.8 | |||||||||
| 2022 | -42.5 | -27.8 | +21.4 | -26.1 | -18.9 | +37.8 | -12.7 | +24.1 | -2.7 | +0.6 | -10.2 | -17.4 |
| 2023 | +29.4 | +16.9 | +46.9 | -12.4 | -4.3 | +22.9 | +101.8 | -12.7 | -13.8 | +2.5 | +7.7 | +30.5 |
| 2024 | -15.2 | +2.5 | -13.2 | -14.5 | +3.6 | -12.6 | +3.0 | +6.4 | -11.4 | -5.6 | +6.3 | +3.2 |
| 2025 | +21.3 | +12.5 | +4.7 | +16.2 | -10.8 | +21.8 | +10.5 | +9.3 | +3.9 | +17.1 | +16.2 | +6.6 |
| 2026 | -1.2 | -15.0 | +13.4 | -4.5 | -3.4 | +14.0 | +7.5 | -4.2 | -14.1 | +0.1 |



